SKYSTAR BIO-PHARMACEUTICAL CO Finite-Lived Intangible Asset, Expected Amortization, after Year Five
SKYSTAR BIO-PHARMACEUTICAL CO had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $3.96 million as of 2013-12-31, per its 10-Q filed 2014-11-14.
Discontinued › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2014-11-14
- 2013-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $3.96M; Finite-Lived Intangible Asset, Expected Amortization, after Year Five as first filed $3.99M.
- 2012-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $4.22M; Finite-Lived Intangible Asset, Expected Amortization, after Year Five as first filed $4.11M.
- 2012-06-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $4.34M.
- 2011-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $4.34M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five | Finite-Lived Intangible Asset, Expected Amortization, after Year Five as first filed |
|---|---|---|
| 2013-12-31 | $3.96M 10-Q · filed 2014-11-14 | $3.99M 10-K · filed 2014-03-31 |
| 2012-12-31 | $4.22M 10-Q · filed 2013-11-14 | $4.11M 10-K · filed 2013-04-01 |
| 2012-06-30 | $4.34M 10-Q/A · filed 2012-09-13 | |
| 2011-12-31 | $4.34M 10-Q · filed 2012-11-14 |